

Supporting Information

Francez-Charlot et al. 10.1073/pnas.0810291106

SI Experimental Procedures

Strain Constructions. For complementation and overexpression studies in *M. extorquens* AM1, plasmid pCM62 and its derivative pCM80, which contains the strong p_{mxaF} promoter, were used (1). To construct the *phyRD190A* allele, an overlapping PCR strategy was used. Two PCR products were generated with primers pCM80_regL-PstI/phyRD190A R and pCM80_regLKpnI/phyRD190A F. PCR products were mixed and reamplified with primers pCM80_regL-PstI/pCM80_regLKpnI. The resulting product and the wild-type *phyR* allele generated with the same primers were cloned into pCM62 to generate pCM62-*phyRD190A* and pCM62-*phyR*, respectively. In these vectors, *phyR* expression was driven from its native promoter. Plasmid pCM80-PhyRNterm to overexpress the N-terminal domain of PhyR was derived from plasmid pBG11 (2) cut with SalI and self-circularized. To overexpress *nepR* (*rmq12793*), a PCR fragment containing the *nepR* ORF and 38 nucleotides upstream of the start codon was generated with primers 3115 -137 F and 3115R3 and was cloned into TOPO PCR2.1 (Invitrogen). The *nepR* ORF was then excised with HindIII and XbaI and cloned in pCM80 to generate pCM80-*nepR*. To construct pCM80-*nepR*-*phyR* for coexpression studies, a PCR fragment containing *phyR* ORF and 19 nucleotides upstream of the start codon made with primers PhyR F1 PstI and PhyR R1 XbaI was cloned into pCM80-*nepR* digested with PstI and XbaI. In the resulting plasmid pCM80-*nepR*-*phyR*, *phyR* was located downstream of *nepR*, with 40 nucleotides between the *nepR* stop codon and the *phyR* start codon.

To overproduce PhyR with a C-terminal hexahistidine tag, the corresponding gene was amplified with primers phyR EXP F1 and phyR EXP R1 and cloned into the pET24b vector using NdeI and NotI restriction sites to generate pET24b-*phyR*. To overproduce and purify the PhyR mutant D190A and the N-terminal ECF domain of PhyR, PCR products generated with primers phyR TP F/phyR TP R and phyR TP F/phyRNterm R were cloned into the Champion pET101 vector (Invitrogen), adding a C-terminal hexahistidine tag to the synthesized protein (plasmids pET101-*phyRD190A* and pET101-*phyRNterm*, respectively). *NepR* and $\sigma^{\text{EcfG1}\Delta 1-64}$ were overexpressed with an N-terminal decahistidine tag. The corresponding genes were amplified with primers *nepR* for/*nepR* rev or 4906 wo Nterm F1/4906 R2 and cloned into the pET16b vector using BamHI and NdeI restriction sites to generate plasmids pET16b-*nepR* and pET16b-*ecfG1* $\Delta 1-64$, respectively.

For *in vivo* interaction studies, the *nepR* gene was amplified using the oligonucleotides *nepR*his-f/*nepR*his-r, adding a C-terminal hexahistidine tag to the construct, and cloned into pCM80 to generate pCM80-*nepR*-his.

To construct the unmarked *ecfG1* (*rmq08147*) deletion mutant, an overlapping PCR was used: 2 PCR fragments of 600 bp

corresponding to upstream and downstream flanking regions of a *rmq08147* ORF were generated with primers META1.4906 Up F/META1.4906 Up R and META1.4906 Down F/META1.4906 Down R; PCR products were then mixed and used in PCR with primers META1.4906 Up F and META1.4906 Down R. The 1.2-kb fragment obtained corresponding to merged 600-bp upstream and downstream regions was cloned into the broad-host-range *sacB*-based vector for unmarked allelic exchange pCM433 (3) using NdeI and AgeI restriction sites. The resulting plasmid, pCM433-*ecfG1*, was transformed in *M. extorquens* by electroporation, and transformants were selected on tetracycline. For sucrose selection, colonies were resuspended in MM and plated on MM supplemented with methanol, succinate, and 5% sucrose. Single colonies were tested for tetracycline resistance, and tetracycline-sensitive strains were analyzed by PCR using primers located outside the region where recombination occurred. Mutant strains were further analyzed by sequencing the region encompassing the locus where recombination had occurred.

Overproduction and Purification of PhyR, NepR, and σ^{EcfG1} . For *in vitro* interaction studies, the different PhyR, NepR, and $\sigma^{\text{EcfG1}\Delta 1-64}$ constructs were produced in *E. coli* BL21 (DE3). Expression was induced at an OD₆₀₀ of 0.8 with 1 mM isopropyl β -D-thiogalactoside. Four hours after induction, cells were harvested by centrifugation and stored at -20°C . For cell-extract preparation, thawed cells were resuspended in 10 mL of TNI5 buffer [20 mM Tris/HCl (pH 8.0), 150 mM NaCl, and 5 mM imidazol], and a protease inhibitor mixture was added (Complete, EDTA-free; Roche). Cell disruption was performed using Bugbuster reagent (Novagen). Intact cells and cell debris were removed by centrifugation (15 min, $8,000 \times g$, 4°C). Afterward, the cell-free extract was subjected to ultracentrifugation (1 h, $150,000 \times g$, 4°C). Recombinant protein present in the supernatant was purified by nickel chelate affinity chromatography using Ni-NTA (HisTrap HP; GE Healthcare). After immobilization of the protein, the column was washed with 15 column volume TNI20 buffer (TNI buffer with 20 mM imidazol), and bound protein was eluted with TNI200 buffer (TNI buffer with 200 mM imidazol). Fractions containing the protein were pooled, and the elution buffer was exchanged against TG buffer [20 mM Tris/HCl (pH 8.0) and 10% (vol/vol) glycerol] and stored at -20°C .

NepR and $\sigma^{\text{EcfG1}\Delta 1-64}$ were purified using Ni-NTA as described for PhyR. Ni-NTA pooled fractions were then applied to a Superdex75 10/300 gel filtration column (Amersham Biosciences) equilibrated with buffer A [50 mM Tris/HCl (pH 8.0) and 150 mM NaCl] at a flow rate of 0.5 mL/min. The major peak fractions were pooled and concentrated, and the buffer was exchanged against TG buffer. Because of stability problems with *NepR*, purified protein was used for *in vitro* interaction studies within 24 h. During the course of σ^{EcfG1} purification, it was noted that σ^{EcfG1} precipitated at concentrations >0.5 mg/mL.

1. Marx CJ, Lidstrom ME (2001) Development of improved versatile broad-host-range vectors for use in methyloprophs and other Gram-negative bacteria. *Microbiology* 147:2065–2075.
2. Gourion B, Rossignol M, Vorholt JA (2006) A proteomic study of *Methylobacterium extorquens* reveals a response regulator essential for epiphytic growth. *Proc Natl Acad Sci USA* 103:13186–13191.

3. Marx CJ (2008) Development of a broad-host-range *sacB*-based vector for unmarked allelic exchange. *BMC Res Notes* 1:1.





Fig. S1. Sequence alignment of PhyR and σ^{EcF1} homologues of selected Alphaproteobacteria. The alignment shows that PhyR homologues lack a part of the region 2.4, involved in -10 binding. In addition, region 4.2, which is involved in -35 binding, shows degeneration in PhyR homologues, compared with the high degree of conservation observed among the different ECF sigma factors. The alignment was generated with Clustal.W. Sequences are based on data deposited in GenBank, except for Mlr3700, where a longer version containing the ECF sigma factor-like domain was taken. Protein labels indicate species as follows: *Bradyrhizobium japonicum* USDA 110, Blr/Bll; *Rhodopseudomonas palustris* CGA009, RPA; *Brucella melitensis* 16M, BMEI; *Sinorhizobium meliloti* 1021, SMc; *Mesorhizobium loti* MAFF303099, Mll; *Shewanella* *crensetus* CB15, CC. Residues conserved in 75% of the sequences are highlighted (BLOSUM.62). Regions 2 and 4 conserved among σ^{70} family are shown above the alignment.

Other Supporting Information Files

- [Table S1](#)
- [Table S2](#)
- [Table S3](#)